← Russell 3000 cross-section

EYPT EyePoint, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$403m
Revenue TTM
$3m
Net income TTM
$-307m
Free cash flow
$-271m
Composite score
25.6
Sector rank
#2507

Valuation

P / E
EV / EBITDA
EV / sales
79.7
FCF yield
-67.38%
Earnings yield vs 10-yr
-80.88pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-10,998.7%
EBITDA margin
-11,255.4%
ROE
-184.3%
ROIC
Revenue growth
-94.6%

Insider activity, last 90 days

Net open-market
$-0.02m
Buyers
1
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

This decrease was primarily driven by the recognition of remaining deferred revenue related to our 2023 agreement for the license of YUTIQ® product rights in the second quarter of 2025. Cost of Sales Cost of sales remained immaterial for the three months ended June 30, 2026 compared to the same period the prior year. Research and Development The following table summarizes our research and development expenses for the three months ended June 30, 2026 and 2025: Research and development expenses increased by $28.1 million, or 51%, to $83.6 million for the three months ended June 30, 2026 compared to the same period the prior year. …EyePoint, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →